Johnson & Johnson's bladder cancer therapy approved by the U.S. FDA

The U.S. Food and Drug Administration has approved Johnson & Johnson's drug delivery system named Inlexzo for the treatment of a type of bladder cancer, providing patients with a potential non-surgical option. The approval of Inlexzo is based on data from a mid-stage study, in which over 82% of patients showed no signs of cancer after receiving Inlexzo treatment, with more than half of the patients remaining cancer-free for at least a year. Guggenheim analyst Vamil Divan estimates that Inlexzo's potential revenue could reach approximately $3.4 billion by 2040